{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "R",
          "alt": "G",
          "position": "1441"
        },
        "variant_string_id": "LRRK2 R1441G"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The study shows that LRRK2 mutations (e.g., R1441G, Y1699C, G2019S) reduce phosphorylation at S935 and impair 14-3-3 binding, which is critical for LRRK2 function in Parkinsonâ€™s disease (PD).",
          "judgment": "Yes",
          "reasoning": "The paper explicitly defines the disease mechanism: impaired 14-3-3 binding due to reduced phosphorylation at S935, directly linking these variants to PD pathogenesis."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study uses phosphorylation and protein interaction assays (e.g., affinity purification, mass spectrometry, and antibody-based binding assays) to assess LRRK2 function.",
          "judgment": "Yes",
          "reasoning": "Phosphorylation and protein interaction assays are well-established methods for evaluating molecular mechanisms in PD and are directly relevant to the disease mechanism defined in Step 1.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic controls/replicates",
          "extracted_paper_info": "The study uses wild-type LRRK2 as a control and demonstrates that R1441G, Y1699C, and G2019S mutations reduce S935 phosphorylation and 14-3-3 binding across multiple tissues and ages.",
          "judgment": "Yes",
          "reasoning": "Controls (wild-type LRRK2) and replicates (multiple tissues/ages) are explicitly described, satisfying Step 3a requirements."
        },
        {
          "step_name": "Step 3c: Variant controls",
          "extracted_paper_info": "The study does not explicitly use known pathogenic or benign variants as controls for these specific mutations.",
          "judgment": "No",
          "reasoning": "Variant controls (e.g., pathogenic/benign variants) are not described, so the functional evidence strength is capped at **Max PS3_supporting**."
        },
        {
          "step_name": "Step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study does not calculate OddsPath or provide statistical metrics (e.g., p-values, effect sizes) for these specific mutations.",
          "judgment": "No",
          "reasoning": "Without OddsPath or statistical analysis, the functional evidence strength remains **Max PS3_supporting**."
        }
      ],
      "final_strength": "PS3_supporting"
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "Y",
          "alt": "C",
          "position": "1699"
        },
        "variant_string_id": "LRRK2 Y1699C"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The study shows that Y1699C reduces phosphorylation at S935 and impairs 14-3-3 binding, linking it to PD pathogenesis.",
          "judgment": "Yes",
          "reasoning": "The paper explicitly defines the disease mechanism: impaired 14-3-3 binding due to reduced phosphorylation at S935, directly linking this variant to PD."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Phosphorylation and protein interaction assays (e.g., affinity purification, mass spectrometry, and antibody-based binding assays) are used to assess LRRK2 function.",
          "judgment": "Yes",
          "reasoning": "These assays are well-established and directly relevant to the disease mechanism defined in Step 1.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic controls/replicates",
          "extracted_paper_info": "The study uses wild-type LRRK2 as a control and demonstrates that Y1699C reduces S935 phosphorylation and 14-3-3 binding across multiple tissues and ages.",
          "judgment": "Yes",
          "reasoning": "Controls (wild-type LRRK2) and replicates (multiple tissues/ages) are explicitly described, satisfying Step 3a requirements."
        },
        {
          "step_name": "Step 3c: Variant controls",
          "extracted_paper_info": "The study does not explicitly use known pathogenic or benign variants as controls for these specific mutations.",
          "judgment": "No",
          "reasoning": "Variant controls are not described, so the functional evidence strength is capped at **Max PS3_supporting**."
        },
        {
          "step_name": "Step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study does not calculate OddsPath or provide statistical metrics (e.g., p-values, effect sizes) for this variant.",
          "judgment": "No",
          "reasoning": "Without OddsPath or statistical analysis, the functional evidence strength remains **Max PS3_supporting**."
        }
      ],
      "final_strength": "PS3_supporting"
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "G",
          "alt": "S",
          "position": "2019"
        },
        "variant_string_id": "LRRK2 G2019S"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The study shows that G2019S reduces phosphorylation at S935 and impairs 14-3-3 binding, linking it to PD pathogenesis.",
          "judgment": "Yes",
          "reasoning": "The paper explicitly defines the disease mechanism: impaired 14-3-3 binding due to reduced phosphorylation at S935, directly linking this variant to PD."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Phosphorylation and protein interaction assays (e.g., affinity purification, mass spectrometry, and antibody-based binding assays) are used to assess LRRK2 function.",
          "judgment": "Yes",
          "reasoning": "These assays are well-established and directly relevant to the disease mechanism defined in Step 1.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic controls/replicates",
          "extracted_paper_info": "The study uses wild-type LRRK2 as a control and demonstrates that G2019S reduces S935 phosphorylation and 14-3-3 binding across multiple tissues and ages.",
          "judgment": "Yes",
          "reasoning": "Controls (wild-type LRRK2) and replicates (multiple tissues/ages) are explicitly described, satisfying Step 3a requirements."
        },
        {
          "step_name": "Step 3c: Variant controls",
          "extracted_paper_info": "The study does not explicitly use known pathogenic or benign variants as controls for these specific mutations.",
          "judgment": "No",
          "reasoning": "Variant controls are not described, so the functional evidence strength is capped at **Max PS3_supporting**."
        },
        {
          "step_name": "Step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study does not calculate OddsPath or provide statistical metrics (e.g., p-values, effect sizes) for this variant.",
          "judgment": "No",
          "reasoning": "Without OddsPath or statistical analysis, the functional evidence strength remains **Max PS3_supporting**."
        }
      ],
      "final_strength": "PS3_supporting"
    }
  ]
}